Dendrimer-Antibody Conjugates: An Innovative Approach for Targeted Intracellular Antibody Delivery

Introduction: Antibody drugs are widely used in the clinic to target disease-relevant molecules in the extracellular space or at cell membranes. However, many key targets are located inside cells, presenting significant delivery challenges. Our lab addresses this by developing dendrimer-antibody conjugates for enhanced intracellular and extracellular activity. Using Adalimumab (ADA), a TNF-α blocker, we created a novel conjugate, HD-ADA, with a hydroxyl-terminated PAMAM dendrimer.This study demonstrates HD-ADA’s targeted delivery, immune modulation, and ability to cross the BBB, targeting reactive microglia

Wathsala Liyanage – Research associates, Centre of nanomedicine, JOHNS HOPKINS UNIVERSITY BLOOMBERG SCHOOL OF PUBLIC HEALTH; Maria Paula Avalos – Postdoctoral Fellow, JOHNS HOPKINS UNIVERSITY BLOOMBERG SCHOOL OF PUBLIC HEALTH; Javier Allende Labastida – Postdoctoral Fellow, JOHNS HOPKINS UNIVERSITY BLOOMBERG SCHOOL OF PUBLIC HEALTH; Sujatha Kannan – Professor, JOHNS HOPKINS UNIVERSITY BLOOMBERG SCHOOL OF PUBLIC HEALTH; Kannan Rangaramanujam – Professor, JOHNS HOPKINS UNIVERSITY BLOOMBERG SCHOOL OF PUBLIC HEALTH